BRIEF published on 02/10/2026 at 09:05, 4 months 16 days ago MVISE AG affiche une forte rentabilité malgré un recul stratégique des ventes Rentabilité Revenus Récurrents Développement Logiciel MVISE AG Baisse Stratégique Des Ventes
PRESS RELEASE published on 02/10/2026 at 09:00, 4 months 16 days ago Original-Research: mVISE AG (von NuWays AG): BUY mVISE AG's strong profitability despite lower sales base in FY25. Strategic shift towards software-centric development models positively impacting recurring sales and EBITDA margins. Management guidance for FY26 looks achievable Sales Profitability Software Development MVISE AG FY25
BRIEF published on 02/09/2026 at 09:31, 4 months 17 days ago MVISE AG Reports Strong Performance Despite Market Challenges in 2025 Software Development Strategic Transformation EBITDA Growth MVISE AG 2025 Financials
BRIEF published on 02/09/2026 at 09:31, 4 months 17 days ago MVISE AG annonce de solides performances malgré les difficultés du marché en 2025 Développement Logiciel Transformation Stratégique Croissance De L'EBITDA MVISE AG Données Financières 2025
PRESS RELEASE published on 02/09/2026 at 09:26, 4 months 17 days ago mVISE AG announces preliminary figures for 2025 mVISE AG announces strong financial results for 2025, with EBITDA up 15% to EUR 1.3 million, recurring customer revenue at 70%, and reduction of long-term liabilities by EUR 750 thousand Financial Results EBITDA Recurring Revenue MVISE AG Long-term Liabilities
BRIEF published on 09/26/2025 at 09:05, 9 months ago MVISE AG Shows Improved Profitability Amid Business Restructuring Investment Platform Financial Restructuring EBITDA Growth Capital Strategy MVISE AG
BRIEF published on 09/26/2025 at 09:05, 9 months ago MVISE AG affiche une rentabilité améliorée malgré la restructuration de son activité Restructuration Financière Croissance De L'EBITDA Plateforme D'investissement Stratégie De Capital MVISE AG
PRESS RELEASE published on 09/26/2025 at 09:00, 9 months ago Original-Research: mVISE AG (von NuWays AG): Buy Update on mVISE AG's financial performance and strategic initiatives. Reiterate Buy rating with a target price of EUR 1.30. Strong margin improvements despite sales decline in H1'25 Financial Performance BUY Rating Strategic Initiatives Margin Improvements MVISE AG
BRIEF published on 07/28/2025 at 11:31, 10 months 29 days ago MVISE AG annonce des mesures de capital stratégique et la continuité de son leadership Mesures Stratégiques Restructuration Du Capital MVISE AG Renouvellement Du Leadership Consolidation Des Obligations
BRIEF published on 07/28/2025 at 11:31, 10 months 29 days ago MVISE AG Announces Strategic Capital Measures and Leadership Continuity Strategic Measures Capital Restructuring MVISE AG Leadership Renewal Bonds Consolidation
Published on 06/26/2026 at 14:05, 35 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 40 minutes ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 1 hour 40 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 01:40, 13 hours ago UraniumX Announces DTC Eligibility for U.S. Traded Shares
Published on 06/26/2026 at 14:00, 40 minutes ago Hong Kong celebrates surge of global enterprises driving investment and opportunities
Published on 06/26/2026 at 14:00, 40 minutes ago Bitcoin Group SE publishes 2025 Annual Report: Strategic realignment ensures future viability in the dynamic crypto market
Published on 06/26/2026 at 13:32, 1 hour 8 minutes ago Porsche ranks number one in J.D. Power 2026 U.S. Initial Quality Study
Published on 06/26/2026 at 13:30, 1 hour 9 minutes ago Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share
Published on 06/26/2026 at 13:30, 1 hour 10 minutes ago AlphaESS Unveils Expanded Energy Storage Ecosystem for Europe at Intersolar 2026
Published on 06/26/2026 at 07:00, 7 hours 40 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 7 hours 40 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 18:45, 19 hours 55 minutes ago Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 20 hours 10 minutes ago Avis financier semestriel SIEHM au 30 avril 2026
